These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 16650499

  • 1. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL, Bhalla S, Laranjeira L, Guerreiro M.
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.
    Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S.
    Lung Cancer; 2004 Jan; 43(1):101-12. PubMed ID: 14698544
    [Abstract] [Full Text] [Related]

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Jan; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 5. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
    Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK.
    Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L.
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ, Brandt A.
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D, Schweisfurth H, Grah C, Schäper C, Temmesfeld-Wollbrück B, Siebert G, Suttorp N, Beinert T.
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [Abstract] [Full Text] [Related]

  • 11. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
    Rubio-Terrés C, Tisaire JL, Kobina S, Moyano A.
    Lung Cancer; 2002 Jan; 35(1):81-9. PubMed ID: 11750717
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.
    González García J, Gutiérrez Nicolás F, Nazco Casariego GJ, Valcárcel Nazco C, Batista López JN, Oramas Rodríguez J.
    Farm Hosp; 2017 Jan 01; 41(n01):3-13. PubMed ID: 28045649
    [Abstract] [Full Text] [Related]

  • 13. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
    Sacristán JA, Kennedy-Martin T, Rosell R, Cardenal F, Antón A, Lomas M, Alberola V, Massuti B, Carrato A, Minshall M.
    Lung Cancer; 2000 May 01; 28(2):97-107. PubMed ID: 10717327
    [Abstract] [Full Text] [Related]

  • 14. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
    Neymark N, Lianes P, Smit EF, van Meerbeeck JP.
    Pharmacoeconomics; 2005 May 01; 23(11):1155-66. PubMed ID: 16277550
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR.
    Clin Cancer Res; 2004 Aug 01; 10(15):5022-6. PubMed ID: 15297403
    [Abstract] [Full Text] [Related]

  • 16. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
    Chisaki Y, Nakamura N, Yano Y.
    Biol Pharm Bull; 2017 Aug 01; 40(1):73-81. PubMed ID: 28049952
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec 01; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 19. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.
    Health Technol Assess; 2013 Jul 01; 17(31):1-278. PubMed ID: 23886301
    [Abstract] [Full Text] [Related]

  • 20. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N.
    Thorax; 2002 Jan 01; 57(1):20-8. PubMed ID: 11809985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.